Biotech | March 23, 2022
GMP certification for Exothera further extends its viral vector manufacturing capacity
The expansion makes Exothera one of the largest viral vector facilities in Europe
The expansion makes Exothera one of the largest viral vector facilities in Europe
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Collaboration in the industry needs to be institutionalised to drive the growth.
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Subscribe To Our Newsletter & Stay Updated
